Berlin-Chemie AG
Berlin-Chemie AG, a prominent player in the pharmaceutical industry, is headquartered in Berlin, Germany. Founded in 1890, the company has established a strong presence in various operational regions, particularly across Europe and Asia. Specialising in the development and production of prescription medicines, Berlin-Chemie focuses on therapeutic areas such as cardiology, oncology, and diabetes care. The company is renowned for its innovative approach to drug formulation, offering unique products that cater to the specific needs of patients and healthcare professionals. With a commitment to quality and research, Berlin-Chemie AG has achieved significant milestones, including numerous partnerships and collaborations that enhance its market position. As a subsidiary of the Menarini Group, Berlin-Chemie continues to expand its influence in the global pharmaceutical landscape, driven by a dedication to improving health outcomes.
DitchCarbon Score
How does Berlin-Chemie AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Berlin-Chemie AG's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Berlin-Chemie AG's reported carbon emissions
Berlin-Chemie AG, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of figures in the latest emissions data. The company is classified as a current subsidiary and does not inherit emissions data from a parent organisation. In terms of climate commitments, there are no documented reduction targets or initiatives such as Science-Based Targets (SBTi) or other climate pledges. This lack of specific commitments suggests that Berlin-Chemie AG may still be in the early stages of formalising its climate strategy. As the pharmaceutical industry increasingly focuses on sustainability, it is essential for companies like Berlin-Chemie AG to establish clear emissions reduction goals and strategies to align with global climate efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Berlin-Chemie AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
